Share on Google Plus Share on Twitter Share on Facebook Share on LinkedIn Share on PInterest Share on Fark! Share on Reddit Share on StumbleUpon Tell A Friend 1 (1 Shares)  
Printer Friendly Page Save As Favorite View Favorites View Stats   No comments

General News

Are You Ready for the New Diet Drugs?

By (about the author)     Permalink       (Page 1 of 2 pages)
Related Topic(s): ; ; ; ; ; ; ; ; ; ; (more...) , Add Tags  (less...) Add to My Group(s)

Must Read 1   News 1   Supported 1  
View Ratings | Rate It

opednews.com Headlined to H4 8/12/12

Become a Fan
  (71 fans)

By now, most people are aware of the obesity statistics. Thirty-four percent of US adults are obese, 34 percent are overweight and more than a third of children are either obese or overweight. The average American man weighs 194 and the average woman, 165--a trend that brings to mind an old New Yorker cartoon in which a doctor tells a fat patient "according to this chart you should be seven feet and two inches tall."

Not everyone agrees on the reasons for the ballooning American physique--is it inactivity? Overeating? The wrong foods? Environmental factors?-- but few dispute that excess weight is linked to coronary heart disease, stroke, Type 2 diabetes, cancer, high blood pressure, liver and gallbladder disease and osteoarthritis. One statistical report says obesity is actually more harmful than smoking, drinking or poverty. And that's assuming the overweight aren't afflicted with those conditions too....

But despite the 200 million Americans who could use a diet pill and the $60 billion a year such a pill represents to Pharma (more than the statin market, $25 billion a year and erectile drug market, $5 billion a year combined!) the FDA has not approved a new diet drugs in 13 years. Worse, the last diet drug it approved, orlistat, found in the prescription drug Xenical and over-the-counter version, Alli has been a disappointment and the "butt" of jokes.

Orlistat causes weight loss by blocking the body's absorption of fat, putting users at risk of "fatty/oily stool, oily evacuation, increased defecation and fecal incontinence," says its prescribing information. Soon after the drugs' approval, comedians let fly one liners like, "With Allies Like This, Who Needs Enemas?" and "Free coupon for Depends." Scat and splat jokes aside, weight loss is also only modest with the fat blockers and in 2010 the FDA added warnings of "severe liver injury" to them.

So it is no surprise that overweight people, the doctors who treat them, Wall Street and Pharma are heartened by the FDA's approval this summer of two new diet drugs. Qsymia, made by Mountain View, CA-based Vivus and Belviq, made by San Diego-based Arena Pharmaceuticals were both turned down by the FDA in 2010 but reconsidered and approved this year when more safety data were presented. Both are expected to hit pharmacy shelves before the end of the year.

Qsymia combines the diet pill phentermine (also known as Fastin, Adipex and Ionamin) with topiramate, the active ingredient in the seizure drug Topamax known to suppress appetite. Even though both ingredients are already on the market and could be prescribed without Qsymia's approval, the FDA rejected the combo pill two years ago over   concerns about depression, memory-loss and birth defects risks. (Months after Qsymia's 2010 rejection, the FDA added birth defect warning to topiramate.)

Belviq is lorcaserin, a never-before-approved antidepressant-like drug similar to two drugs withdrawn from the market for deadly heart valve problems in 1997. The FDA rejected Belviq in 2010 because of tumors in rats given the drug causing Arena to lay off 66 employees and prompting a petition to the FDA charging that, "The dramatic elevation of concern over rat cancer," could "result in irreparable damage to the bio-technology and pharmaceutical industry as a whole."

Of course dangerous diet drugs have also caused "irreparable damage to the bio-technology and pharmaceutical industry," which is why the FDA has been so gun shy in approving a new diet med. Fen-Phen, which combined phentermine (found in the just-approved drug Qsymia) and dexfenfluramine or fenfluramine (similar to the just-approved Belviq) was withdrawn as a combination drug in 1997 for causing primary pulmonary hypertension (PPT) and heart valve deaths. The drug's lethal side effects were especially embarrassing to the FDA since its own reviewer had predicted them if the two drugs were combined but his veto was overridden and the drug was approved anyway. Oops.

The same year Fen-Phen was withdrawn, the FDA approved the diet drug sibutramine (Meridia) which was also withdrawn from the market in   2010 for cardiovascular problems! In fact, the appetite reducing action of diet drugs and heart problems can be so closely linked, an FDA advisory committee voted earlier this year to require all obesity drugs to undergo more stringent clinical trials to assess cardiovascular risks.

Now, the FDA is taking no chances with the newly approved drugs. "Qsymia can increase heart rate; this drug's effect on heart rate in patients at high risk for heart attack or stroke is not known. Therefore, the use of Qsymia in patients with recent (within the last six months) or unstable heart disease or stroke is not recommended. Regular monitoring of heart rate is recommended for all patients taking Qsymia, especially when starting Qsymia or increasing the dose," said the FDA in approving the new diet pill. Similar warnings appear for Belviq.

Both drugs are strictly approved for adults with "initial body mass index (BMI) of 30 kg/m2" and other obesity-related risks factors--not for people who are a size 4 and want to be a size 2. They are also approved as "adjuncts to reduced-calorie diet and increased physical activity for chronic weight management," meaning that patients have to do some of the heavy lifting too. And patients are cautioned to not stay on the drugs if they aren't working and to have close doctor supervision even when they are.


creeping obesity by Martha Rosenberg

To keep "pill mills" from sprouting up with the new drugs as they did in the 1990s to cash in on the popularity of Fen-Phen before it was withdrawn, the FDA has also tightened the new drugs' availability. Doctors must prescribe Qsymia through a certified pharmacy and cannot stock it themselves reports NBC News   and Belviq will likely be controlled by the Drug Enforcement Administration (DEA) like opiate painkillers.

How well will the new drugs actually work? In clinical trials, Qsymia users lost up to 10 percent of their total body weight. Besides the appetite suppressing phentermine, Qsymia contains topiramate which users actually complain makes them lose too much weight because it makes food and beverages taste bad. Of course the ten percent weight loss comes at the price of a risk of birth defects, a warning which is clearly marked.

In clinical trials, Belviq users lost up to five percent of their total body weight, considerably less than with Qsymia. But some are predicting doctors or patients may add phentermine to Belviq and create a neo Fen-Phen since Belviq's ingredient is similar to the withdrawn ingredient in Fen-Phen. Few had liked the drowsiness, memory loss and mood changes caused by the withdrawn "fen" drug but when phentermine (now in Qsymia) was added--it counteracted the effects and maximized the weight loss. Anticipating the desire on the part of patients or doctors to reconstitute a "Fen-Phen," Belviq's prescribing information warns against "coadministration" of other weight loss   drugs and even mentions phentermine by name." Certainly the warning covers topiramate (the other ingredient in Qsymia)--as well as taking all three active ingredients together.

It is not clear whether insurance will cover Qsymia and Belviq which are projected to cost $100 to $200 a month (or more). Despite the well-documented expenses of treating obesity-related health problems, Medicare doesn't cover diet drugs, reports the industry site FiercePharma. Few state Medicaid programs cover diet drugs either and private insurers often ask patients to share the cost.

Next Page  1  |  2

 

Martha Rosenberg is an award-winning investigative public health reporter who covers the food, drug and gun industries. Her first book, Born With A Junk Food Deficiency: How Flaks, Quacks and Hacks Pimp The Public Health, is distributed by Random (more...)
 

Share on Google Plus Submit to Twitter Add this Page to Facebook! Share on LinkedIn Pin It! Add this Page to Fark! Submit to Reddit Submit to Stumble Upon

Go To Commenting
The views expressed in this article are the sole responsibility of the author and do not necessarily reflect those of this website or its editors.

Writers Guidelines

Contact Author Contact Editor View Authors' Articles

Most Popular Articles by this Author:     (View All Most Popular Articles by this Author)

Grassley Investigates Lilly/WebMD link Reported by Washington Post

The Drug Store in Your Tap Water

Are You Sure You're Not Psychotic Asks Shameless Drug Company?

It's the Cymbalta Stupid

MRSA and More. Antibiotics Linked to Obesity and Allergies, Too

Another Poorly Regulated "Derivative"--the Antidepressant Pristiq

Comments

The time limit for entering new comments on this article has expired.

This limit can be removed. Our paid membership program is designed to give you many benefits, such as removing this time limit. To learn more, please click here.

Comments: Expand   Shrink   Hide  
No comments